Hester Biosciences reported Q1 FY26 results showing a 14% decline in total sales and a 7% drop in standalone profit, but a 131% increase in consolidated profit with sales in the Poultry division rising by 2%. This decline is attributed to delays in government immunization programs, which are expected to resume in future quarters.